StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)
August 21, 2026 6:59 AM
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Rani Therapeutics (NASDAQ: RANI).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments